
OSLO, May 12 (Reuters) - Weight-loss and diabetes drug maker Novo Nordisk NOVOb.CO will engage with the U.S. government over U.S. policy proposals to bring down prices, the Danish company said in a statement to news agency Ritzau on Monday.
"We agree that Americans need access to medicines at better prices, and we will continue to engage with policymakers to develop and implement more effective solutions," Ritzau quoted Novo Nordisk as saying.